A Randomized Trial of Rifaximin vs Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome
Clinical Gastroenterology and Hepatology · 2026-04
DOI: 10.1016/j.cgh.2026.04.014 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-04. Verfasst von Allen A Lee und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: allenlee@med.umich.ed…. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, AHRQ HHS.
Abstract (Originalsprache)
BACKGROUND & AIMS: The low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet (LFD) and rifaximin are effective in
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: allenlee@med.umich.edu.
- Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, University of Michigan, Ann Arbor, Michigan.
- Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
- Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Department of Internal Medicine, Huntington Health-An Affiliate of Cedars-Sinai, Pasadena, California.
- Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Division of Gastroenterology and Hepatology, Kaiser Permanente, Panorama City, California.
- Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Department of Lifestyle Medicine, Trinity Health Ann Arbor, Ypsilanti, Michigan.
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- AHRQ HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- Agency for Healthcare Research and Quality
- University of Michigan
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases Division of Intramural Research
Zitieren
APA
Lee, A. A., Rao, K., Singh, P., Fehlman, J., Gao, J., Takakura, W., Lynett, A., Haller, E., Ball, S., Marand, A., Liu, A., Shah, E., Menees, S., Punglia, R., Nojkov, B., Eswaran, S., Baker, J., Chey, W. D., Owyang, C., …, & Hasler, W. L. (2026). A Randomized Trial of Rifaximin vs Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.04.014
Vancouver
Lee AA, Rao K, Singh P, Fehlman J, Gao J, Takakura W, et al. A Randomized Trial of Rifaximin vs Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.04.014
BibTeX
@article{Lee2026,
author = {Lee, Allen A and Rao, Krishna and Singh, Prashant and Fehlman, Jared and Gao, Jun and Takakura, Will and Lynett, Amanda and Haller, Emily and Ball, Sarah and Marand, Alicia and Liu, Amy and Shah, Eric and Menees, Stacy and Punglia, Raani and Nojkov, Borko and Eswaran, Shanti and Baker, Jason and Chey, William D and Owyang, Chung and Young, Vincent and Hasler, William L},
title = {A Randomized Trial of Rifaximin vs Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.04.014}
}
EUVIMED